US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
ヨーロッパ
EU
OSE Immunotherapeutics (OSE)
OSE Immunotherapeutics (OSE) ニュース

OSE

OSE Immunotherapeutics (OSE)

OSE Immunotherapeutics

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:OSE

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/14	02 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer	EU:OSE	OSE Immunotherapeutics
2024/12/12	02 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®	EU:OSE	OSE Immunotherapeutics
2024/12/03	02 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics Strengthens Leadership and Executive Committee	EU:OSE	OSE Immunotherapeutics
2024/11/04	15 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis	EU:OSE	OSE Immunotherapeutics
2024/10/18	01 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index	EU:OSE	OSE Immunotherapeutics
2024/09/27	01 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update	EU:OSE	OSE Immunotherapeutics
2024/09/10	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer	EU:OSE	OSE Immunotherapeutics
2024/07/24	15 : 55	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis	EU:OSE	OSE Immunotherapeutics
2024/07/04	01 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer	EU:OSE	OSE Immunotherapeutics
2024/07/04	01 : 00	GlobeNewswire Inc.	Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371	EU:OSE	OSE Immunotherapeutics
2024/07/04	01 : 00	GlobeNewswire Inc.	Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371	EU:OSE	OSE Immunotherapeutics
2024/07/03	01 : 00	GlobeNewswire Inc.	Informations relatives au nombre total de droits de vote et d’actions composant le capital	EU:OSE	OSE Immunotherapeutics
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/06/24	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies	EU:OSE	OSE Immunotherapeutics
2024/06/24	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies	EU:OSE	OSE Immunotherapeutics
2024/06/24	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T	EU:OSE	OSE Immunotherapeutics
2024/06/20	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)	EU:OSE	OSE Immunotherapeutics
2024/06/20	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)	EU:OSE	OSE Immunotherapeutics
2024/06/20	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)	EU:OSE	OSE Immunotherapeutics
2024/06/20	01 : 15	GlobeNewswire Inc.	OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société	EU:OSE	OSE Immunotherapeutics
2024/06/20	01 : 15	GlobeNewswire Inc.	OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth	EU:OSE	OSE Immunotherapeutics
2024/06/20	01 : 15	GlobeNewswire Inc.	OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth	EU:OSE	OSE Immunotherapeutics
2024/06/13	01 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse	EU:OSE	OSE Immunotherapeutics
2024/06/13	01 : 00	GlobeNewswire Inc.	OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse	EU:OSE	OSE Immunotherapeutics
2024/06/13	01 : 00	GlobeNewswire Inc.	Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules	EU:OSE	OSE Immunotherapeutics
2024/06/05	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	EU:OSE	OSE Immunotherapeutics
2024/06/05	14 : 30	GlobeNewswire Inc.	OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale	EU:OSE	OSE Immunotherapeutics
2024/06/05	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	EU:OSE	OSE Immunotherapeutics

Showing the most relevant articles for your search:EU:OSE

1 2 3 4 次へ >>

JP Morgan Chase

US Dollar vs Euro

Financial Select Sector

BNP Paribas (QX)

Energy Select Sector SPDR

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約